Print Page      Close Window

Press Release

Tocagen to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall, chief executive officer, will present at the following upcoming investor conferences:

  • Stifel Nicolaus Healthcare Conference, Tuesday, November 14, 11:45 a.m. ET in New York City
  • Evercore ISI Biopharma Catalyst/Deep Dive Conference, Wednesday, November 29, 2:00 p.m. ET in Boston

Tocagen Inc. (PRNewsfoto/Tocagen Inc.)

The live audio webcast from the conferences and subsequent replay may be accessed by visiting Tocagen's website. The webcasts will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, timing and success of our clinical trials and planned clinical trials, timing of results from our clinical trials and our plans regarding selection of additional product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; and our estimates regarding expenses, future revenue and capital requirements. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Tocagen's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Tocagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


View original content with multimedia:

SOURCE Tocagen Inc.

Media Contact: Monica May, Canale Communications, (619) 849-5383, or Investor Contact: Elizabeth Broder, The Trout Group, (646) 378-2945,